Alpha-lipoic acid dose for neuropathy: what 600 mg is based on
The most-cited dose is 600 mg of alpha-lipoic acid a day, which comes from diabetic neuropathy trials: oral 600 mg once daily improved symptoms over five weeks in the SYDNEY 2 trial, and pooled trials of 600 mg given intravenously for three weeks also showed benefit. These are study doses in people with diabetic nerve symptoms, not an established recommended intake — ALA has no RDA or upper limit. Higher doses caused more nausea without a clearly better balance of benefit, and long-term effects on nerve damage are not established.
This article answers one question. For what Alpha-Lipoic Acid is, where it comes from and its other uses, see the Alpha-Lipoic Acid ingredient guide.
Key findings
- The 600 mg figure comes from trial design in diabetic polyneuropathy, not from a nutritional requirement.
- Oral evidence is short-term; the largest pooled evidence is for intravenous ALA.
- Higher oral doses (1,200–1,800 mg) increased digestive side effects.
- Key trials had pharmaceutical-company involvement, and benefits for non-diabetic nerve pain are not established.
What human research has studied
Alpha-lipoic acid (ALA) research for nerve symptoms has focused almost entirely on diabetic peripheral neuropathy — burning, stabbing pain, tingling and numbness in the feet of people with diabetes. The main outcomes are symptom scores such as the Total Symptom Score (TSS), which rates pain, burning, pins-and-needles and numbness, and clinical examination scores.
Two kinds of trial matter, and they are easy to confuse:
- Intravenous ALA: a meta-analysis of four trials (1,258 patients) found that 600 mg a day given by infusion over three weeks improved neuropathic symptoms and deficits compared with placebo [2]. Infusions are a medical treatment, not a supplement.
- Oral ALA: the SYDNEY 2 trial randomised 181 people with diabetic polyneuropathy to 600 mg, 1,200 mg or 1,800 mg of oral ALA once daily, or placebo, for five weeks. All doses improved symptom scores, and the authors concluded that 600 mg once daily offered the best balance of benefit and side effects [1].
Where the evidence is uncertain
ALA’s oral evidence is short-term, and much of it is linked to one manufacturer: the intravenous meta-analysis drew its trials from a pharmaceutical company’s database (VIATRIS), and several SYDNEY 2 investigators reported honoraria and research grants from MEDA, a pharmaceutical company [1][2]. A 2025 meta-analysis concluded that ALA improves several neuropathy measures and noted a dose-dependent trend, with higher doses (1,200–1,800 mg) producing larger symptom changes but more gastrointestinal side effects, particularly nausea [3]. The NCCIH: Diabetes and dietary supplements is more cautious, describing ALA as possibly helpful for diabetic neuropathy pain within a body of supplement research that is generally limited [4]. The reasonable reading is that short-term symptom benefit is supported; long-term nerve protection is not established.
Evidence table
| Study or source | Population | What was tested | Main result | Limitations |
|---|---|---|---|---|
| SYDNEY 2, 2006 [1] | 181 people with diabetic polyneuropathy | Oral ALA 600, 1,200 or 1,800 mg once daily vs placebo, 5 weeks | Symptoms and deficits improved; 600 mg judged best risk–benefit | Short; several investigators had pharmaceutical-company ties |
| Ziegler et al., 2004 [2] | 4 trials; 1,258 patients | Intravenous ALA 600 mg/day for 3 weeks vs placebo | Improved positive symptoms and neuropathic deficits | IV, not oral; trials drawn from a company database |
| Alpha lipoic acid: advancing insights in diabetic neuropathy through updated systematic review and meta-analysis (2025) [3] | Pooled RCTs in diabetic neuropathy | Oral and IV ALA at various doses | Improvements in several symptom and examination scores; dose-dependent GI effects | Heterogeneous trials and doses |
| NCCIH: Diabetes and dietary supplements [4] | Evidence overview | Supplements for diabetes and complications | ALA might help pain from diabetic neuropathy; evidence limited | Summary rather than new data |
Doses: what each number means
| Amount | What kind of figure it is | Context |
|---|---|---|
| 600 mg once daily (oral) | Study dose | Dose judged to offer the best benefit–side-effect balance in SYDNEY 2 (5 weeks) |
| 1,200–1,800 mg daily (oral) | Study dose | Higher SYDNEY 2 arms; more gastrointestinal side effects |
| 600 mg/day intravenously for 3 weeks | Study dose | Infusion regimen in pooled trials — a medical treatment |
| No RDA or upper limit | Regulatory | ALA is not an essential nutrient; no dietary reference values exist |
| 300 mg or 600 mg per capsule | Commercial dose | Common label amounts; check daily serving and form (R-ALA vs standard) |
A dose used in a study describes what researchers gave participants. It is not a personal recommendation, and it does not mean a lower or higher amount is safe or effective for you.
The body makes small amounts of ALA, and it is not classed as an essential nutrient, so there is no recommended intake or tolerable upper limit. The 600 mg figure seen on many labels comes from trial design, not from a dietary reference value.
Form differences
- Intravenous vs oral: the largest pooled evidence is for infusions. Oral results come mainly from shorter trials and should not be assumed to match intravenous effects.
- Racemic ALA vs R-ALA: supplements sell standard ALA (a mix of R and S forms) or R-ALA alone. R-ALA is marketed as the more active form, but the clinical trials summarised here do not establish that an R-ALA dose produces the same symptom benefit as the doses tested.
- Sustained-release products: claims about longer blood levels are not the same as evidence of better symptom outcomes.
Safety
- Digestive side effects: nausea and other gastrointestinal effects become more common at higher doses [3].
- Blood glucose: ALA may lower blood glucose, which matters for people using glucose-lowering medicines.
- Not a substitute for care: neuropathy in diabetes also calls for glucose control, foot checks and, where needed, prescription pain treatment.
Interactions
- Diabetes medicines: monitor glucose more closely if adding ALA to insulin or oral glucose-lowering drugs.
- Chemotherapy: ask the oncology team before using antioxidant supplements during treatment.
- Multi-ingredient nerve formulas: check for other glucose-lowering or sedating ingredients combined with ALA.
Populations requiring caution
- People with diabetes using insulin or sulfonylureas.
- Pregnant or breastfeeding people, for whom safety data are limited.
- People having cancer treatment.
- Anyone with rapidly worsening numbness, weakness, foot ulcers or neuropathy without a known cause — these need assessment, including B12 testing.
Limitations of the research
- Oral trials are short (weeks rather than years).
- Evidence is concentrated in diabetic neuropathy; it does not transfer automatically to sciatica, chemotherapy-induced neuropathy or other nerve pain.
- Pharmaceutical-company involvement in key trials and pooled analyses.
- Symptom scores can be influenced by placebo response, which is substantial in neuropathic pain trials.
Practical label reading
- Check the ALA amount per capsule and per daily serving; some products list 300 mg per capsule with a two-capsule serving.
- Note whether the product uses R-ALA or standard ALA; R-ALA amounts are not directly comparable with the trial doses above.
- In blends, check whether ALA is disclosed or hidden in a proprietary total.
- Look for added B vitamins and check total B6, as high long-term B6 intake can itself affect nerves.
For products built around ALA, see our nerve support supplements comparison and reviews of Nervora and NerveAlive. Browse the nerve health category or read what alpha-lipoic acid is good for.
Frequently asked questions
What dose of alpha-lipoic acid was used for diabetic neuropathy?
Oral trials commonly used 600 mg once daily; SYDNEY 2 also tested 1,200 and 1,800 mg. The strongest pooled evidence used 600 mg a day intravenously for three weeks. These are study doses, not personal recommendations.
Is a higher dose more effective?
Higher doses produced somewhat larger symptom changes in some analyses, but also more nausea and other digestive side effects. SYDNEY 2 authors judged 600 mg the best balance.
How long did it take to work in trials?
Oral trials such as SYDNEY 2 measured symptom changes over five weeks. Long-term benefit on nerve damage is not established.
Is R-ALA better than regular ALA?
R-ALA is marketed as more active, but the trials summarised here do not establish that R-ALA doses are equivalent to the doses tested.
Does ALA help sciatica or other nerve pain?
The main evidence is for diabetic neuropathy. Sciatica is usually caused by nerve-root compression and has not been shown to respond to ALA.
Can ALA lower blood sugar?
It may, so people using diabetes medicines should monitor glucose and talk to their clinician before starting.
References
- Ziegler D, Ametov A, Barinov A, et al. Oral treatment with alpha-lipoic acid improves symptomatic diabetic polyneuropathy: the SYDNEY 2 trial. Diabetes Care. 2006;29(11):2365–2370. PMID 17065669
- Ziegler D, Nowak H, Kempler P, Vargha P, Low PA. Treatment of symptomatic diabetic polyneuropathy with the antioxidant alpha-lipoic acid: a meta-analysis. PMID 14984445
- Alpha lipoic acid: advancing insights in diabetic neuropathy through updated systematic review and meta-analysis (2025).
- NCCIH: Diabetes and dietary supplements.